Adaptive Biotechnologies
ADPT
221 hedge funds and large institutions have $1.74B invested in Adaptive Biotechnologies in 2022 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 88 increasing their positions, 48 reducing their positions, and 39 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 48
26% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 39
3% more funds holding
Funds holding: 214 → 221 (+7)
1.23% more ownership
Funds ownership: 87.48% → 88.71% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
43% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $2.09M
50% less capital invested
Capital invested by funds: $3.46B → $1.74B (-$1.72B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$31.6M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$18.5M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$15.4M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$14.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$58.8M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$26.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$22.1M |
| 4 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
-$19.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.9M |
ADPT Hedge Fund Activity: Q1 2022 in Review
221 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q1 2022, worth a combined $1.74B — down 50% from $3.46B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ADPT positions and 39 closed out — a net gain of 10 holders — while 88 added to existing stakes and 48 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $31.6M. The largest seller was Capital International Investors, exiting entirely with an estimated $58.8M sold.
- 221 institutional investors held Adaptive Biotechnologies (ADPT) as of Q1 2022, up from 214 in Q4 2021.
- Funds reported $1.74B of Adaptive Biotechnologies stock for Q1 2022, down 50% quarter-over-quarter.
- 49 funds opened new Adaptive Biotechnologies positions in Q1 2022 and 39 closed out, a net change of +10 holders.
- The largest Adaptive Biotechnologies buyer in Q1 2022 was ARK Investment Management, an estimated $31.6M added.
- The largest Adaptive Biotechnologies seller in Q1 2022 was Capital International Investors, an estimated $58.8M sold.
Based on aggregated 13F filings for Q1 2022.